Granules India share price
NSE: GRANULESBSE: 532482Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 23 Oct 2026. Previous close ₹817.00.
- Next results date: the board meets on 2 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹21,679 Cr403rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 21 Jul 2026
- 32.7
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.22%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 21 Jul 2026
- 15.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 21 Jul 2026
- 15.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 Apr 2026
- 0.26
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 8,83,84352.9% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 21 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,477 Crup 0.42%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹180 Crdown 10.72%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 12.2%
Revenue by year
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 6 Nov | Dec 2024Filed 24 Jan | Mar 2025Filed 12 Jun | Jun 2025Filed 12 Aug | Sep 2025Filed 13 Nov | Dec 2025Filed 23 Jan | Mar 2026Filed 29 Apr | Jun 2026Filed 21 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 967 | 1,138 | 1,197 | 1,210 | 1,297 | 1,388 | 1,471 | 1,477 |
| Net profit | 97 | 118 | 152 | 113 | 131 | 150 | 202 | 180 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 10.1% | 10.3% | 12.7% | 9.3% | 10.1% | 10.8% | 13.7% | 12.2% |
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/B: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned. Not shown, EV/EBITDA: the share count changed after the latest balance sheet (a rights issue, a buyback, an allotment or a listing), which does not yet hold the money it brought or returned.PE ratio and valuation history
At or below today's level on 97% of 2,453 trading days over the last 10 years.
At or below today's level on 6% of 2,468 trading days over the last 10 years.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +27.8% | +18.3% | +7.9% | 0.3% |
| 3 years | +29.1% | +5.1% | +22.4% | 0.3% |
| 5 years | +15.8% | +2.1% | +13.0% | 0.4% |
Mutual funds holding it
89 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 61 of the 72 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.Mutual fund holdings
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 43
- CutCut. Funds that held fewer shares than at the end of the month before.
- 29
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 16
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end.
- 1
| Fund | |||
|---|---|---|---|
 Old Bridge Focused FundOld Bridge Mutual Fund | 16,50,500 | 3.08% | ₹139.7 Cr |
 Aditya Birla Sun Life Multi-Cap FundAditya Birla Sun Life Mutual Fund | 16,04,464 | 1.87% | ₹135.8 Cr |
| Aditya Birla Sun Life Small Cap FundAditya Birla Sun Life Mutual Fund | 14,13,691 | 1.96% | ₹119.7 Cr |
| Aditya Birla Sun Life Value FundAditya Birla Sun Life Mutual Fund | 14,03,100 | 1.78% | ₹118.8 Cr |
 Sundaram Aggressive Hybrid FundSundaram Mutual Fund | 12,41,794 | 1.20% | ₹105.1 Cr |
 Trustmf Small Cap FundTrust Mutual Fund | 6,58,330 | 1.44% | ₹55.7 Cr |
| Sundaram Small Cap FundSundaram Mutual Fund | 5,00,000 | 1.03% | ₹42.3 Cr |
| Sundaram Multi Asset Allocation FundSundaram Mutual Fund | 4,26,926 | 1.13% | ₹36.1 Cr |
 Nippon India Nifty Smallcap 250 Index FundNippon India Mutual Fund | 2,28,057 | 0.56% | ₹19.3 Cr |
| Sundaram Dynamic Asset Allocation FundSundaram Mutual Fund | 2,01,094 | 1.07% | ₹17.0 Cr |
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Granules India in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Acutaas ChemicalsACUTAAS | 25,689 | 66.5 | 15.5 | 47.0 | +40.9% | +104.3% | 26.1% | 29.1% | 0.08% |
 Piramal PharmaPPLPHARMA | 25,438 | – | 3.1 | 29.4 | +0.8% | −419.8% | −3.9% | 1.1% | 0.00% |
 Neuland LaboratoriesNEULANDLAB | 24,204 | 48.6 | 12.9 | 31.5 | +78.3% | +182.6% | 29.3% | 32.1% | 0.18% |
 Rubicon ResearchRUBICON | 23,578 | 81.8 | 18.3 | 52.2 | – | – | 22.4% | 25.8% | 0.11% |
 Cohance LifesciencesCOHANCE | 17,211 | 162.0 | 4.4 | 54.8 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
 Shilpa MedicareSHILPAMED | 16,904 | 56.9 | 6.5 | 36.6 | +27.9% | +167.6% | 12.0% | 10.9% | 0.07% |
 Caplin Point LaboratoriesCAPLIPOINT | 16,890 | 25.4 | 4.7 | 20.4 | +15.0% | +17.7% | 20.7% | 19.8% | 0.36% |
 PfizerPFIZER | 16,525 | 22.5 | 3.9 | 14.2 | +10.7% | −9.1% | 17.5% | 21.0% | 2.08% |
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.| Ex-date | Type | Per share |
|---|---|---|
| 30 Jul 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.75 |
| 31 Jul 2025 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
| 30 Jul 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
| 3 Aug 2023 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹1.50 |
| 19 Jul 2022 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.75 |
| 17 Feb 2022 | Interim | ₹0.25 |
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
26 Sep · Analysts
23 Sep · Analysts
Granules India share price by year
Each calendar year to 2025.Granules India share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 598.50 | +1.0% | 617.35 | 431.10 |
| 2024 | 592.30 | +46.1% | 718.10 | 392.10 |
| 2023 | 405.45 | +27.2% | 405.45 | 270.95 |
| 2022 | 318.80 | −5.2% | 378.65 | 233.35 |
| 2021 | 336.20 | −4.5% | 386.85 | 294.15 |
| 2020 | 352.15 | +186.1% | 428.00 | 116.85 |
| 2019 | 123.10 | +37.2% | 131.30 | 84.80 |
| 2018 | 89.75 | −34.7% | 146.75 | 72.80 |
| 2017 | 137.45 | +27.2% | 152.05 | 101.20 |
| 2016 | 108.05 | −27.4% | 150.50 | 99.10 |
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 813.00 | 822.00 | 791.00 | 794.75 | 803.81 | 8,83,843 | 52.9% |
| 22 Oct 2026 | 807.00 | 820.25 | 796.05 | 817.00 | 811.11 | 5,12,091 | 56.8% |
| 21 Oct 2026 | 803.00 | 814.45 | 794.15 | 807.65 | 805.98 | 6,57,725 | 54.8% |
| 19 Oct 2026 | 818.90 | 836.95 | 799.30 | 806.05 | 820.84 | 8,74,275 | 37.7% |
| 16 Oct 2026 | 815.00 | 833.50 | 801.90 | 825.35 | 822.12 | 7,72,564 | 48.5% |
| 15 Oct 2026 | 814.80 | 827.50 | 803.25 | 811.95 | 817.45 | 7,84,945 | 43.0% |
| 14 Oct 2026 | 812.05 | 817.00 | 804.00 | 809.10 | 809.77 | 4,04,587 | 46.7% |
| 13 Oct 2026 | 802.95 | 818.00 | 782.05 | 814.50 | 803.72 | 8,13,974 | 44.1% |
| 12 Oct 2026 | 811.15 | 819.80 | 796.10 | 803.35 | 809.08 | 6,24,704 | 58.1% |
| 9 Oct 2026 | 815.05 | 835.85 | 809.65 | 815.25 | 822.51 | 6,03,580 | 41.8% |
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 23 Mar 2015 | Split | 0.1000 | Each share became 10. |
About Granules India
Granules India Limited is a pharmaceutical company with four lines of business: active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), finished dosages (FDs) and peptide contract development and manufacturing (CDMO). It runs an integrated business model across APIs, PFIs and finished dosages, and sells to pharmaceutical customers in regulated and emerging markets.
Its core products include paracetamol, metformin, ibuprofen and controlled substances. Finished dosages are the largest division of the business and cover both prescription and over-the-counter products. The peptide CDMO operations emerged as a distinct business vertical during the year to March 2026. North America is the largest market, and Europe is the market that grew fastest in that year.
The manufacturing network spans India, the USA and Switzerland. In India, plants are located in Telangana and Andhra Pradesh, including Jeedimetla, Bonthapally and Gagillapur in Telangana and Vizag in Andhra Pradesh. A further site is in Virginia in the USA, and the Granules Life Sciences facility is also in Telangana. The peptide CDMO site is at Dielsdorf in Switzerland, and a peptide platform in India works from a Centre of Excellence at IIT Hyderabad. The registered office is in Hyderabad, Telangana.
The company was incorporated in 1991. In the year to March 2026 it completed the acquisition of Senn Chemicals AG in Switzerland, which marked its entry into peptide CDMO.
- Legal name
- Granules India Limited
- NSE symbol
- GRANULES
- BSE code
- 532482
- ISIN
- INE101D01020
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Dec 2002 on BSE, Jun 2005 on NSE
- Face value
- ₹1
- CIN
- L24110TG1991PLC012471
- Corporate identity number, the registrar of companies' code for it